Journal article

Short-Term Effects of Gender-Affirming Hormone Therapy on Dysphoria and Quality of Life in Transgender Individuals: A Prospective Controlled Study

Lucas Foster Skewis, Ingrid Bretherton, Shalem Y Leemaqz, Jeffrey D Zajac, Ada S Cheung

FRONTIERS IN ENDOCRINOLOGY | FRONTIERS MEDIA SA | Published : 2021

Abstract

Background: Gender affirming hormone therapy (GAHT), whilst considered the standard of care in clinical guidelines for the treatment of many transgender (trans) people is supported by low quality evidence. In this prospective longitudinal controlled study, we aimed to examine the effect of newly commencing GAHT on gender dysphoria and quality of life (QoL) over a 6 month period. Methods: Adult trans (including those with binary and/or non-binary identities) people newly commencing standard full-doses of masculinising (n = 42; 35 = trans masculine, 7 = non-binary) or feminising (n = 35; 33 = trans feminine, 2 = non-binary) GAHT and cisgender participants (n=53 male, n=50 female) were recruite..

View full abstract

Grants

Awarded by National Health and Medical Research Council of Australia Early Career Fellowship


Funding Acknowledgements

AC is supported by a National Health and Medical Research Council of Australia Early Career Fellowship (Grant number: 1143333). This study was supported by funding received from Austin Medical Research Foundation, Endocrine Society of Australia, RACP Foundation and Viertel Charitable Foundation. IB is supported by an Australian Postgraduate Award.